[Sinovac Reports Unaudited First Quarter 2019 Financial Results BEIJING, China, July 10, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quart]
[Sinovac Reports Unaudited First Quarter 2019 Financial Results BEIJING, China, July 10, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quart]
[Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F Second Half of 2018 Financial Highlights Ÿ Sales for the second half of 2018 were $107.2 million, which remains the same compared to $107.4 million in the prior year period. Revenue generated by]
[Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F Second Half of 2018 Financial Highlights Ÿ Sales for the second half of 2018 were $107.2 million, which remains the same compared to $107.4 million in the prior year period. Revenue generated by]
[None None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 71,139,402 common shares as of December 31, 2018 ☐ Yes ☒ No ☐ Yes ☒ No ☒ Yes ☐ No ☒ Yes ☐ No ☐ Large] [Contract ]
[None None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 71,139,402 common shares as of December 31, 2018 ☐ Yes ☒ No ☐ Yes ☒ No ☒ Yes ☐ No ☒ Yes ☐ No ☐ Large] [Contract ]
[Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease · The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly t]
[Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease · The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly t]
[Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares April 12, 2019 05:04 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an updat]
[Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares April 12, 2019 05:04 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an updat]
